Literature DB >> 26611336

Challenges in Antimalarial Drug Treatment for Vivax Malaria Control.

Jean Popovici1, Didier Ménard2.   

Abstract

Plasmodium vivax is the most widespread human malaria parasite, but has received much less attention than Plasmodium falciparum during the past 50 years of research. Plasmodium vivax was historically seen as causing only benign disease, but this view has recently changed, with increased recognition of the burden of vivax malaria, as well as numerous case reports of severe malaria or death caused by this parasite. The complexity of P. vivax biology is characteristic of specific features of the parasite, and recent years have seen major progress in our understanding of this complexity. In this review, we analyze the latest advances in the field, describing the constraints that the unique features of P. vivax place on drug treatments aimed at controlling or eliminating it.
Copyright © 2015. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26611336     DOI: 10.1016/j.molmed.2015.10.004

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  11 in total

1.  Genetic diversity of the Plasmodium vivax phosphatidylinositol 3-kinase gene in two regions of the China-Myanmar border.

Authors:  Huguette Gaelle Ngassa Mbenda; Weilin Zeng; Yao Bai; Faiza Amber Siddiqui; Zhaoqing Yang; Liwang Cui
Journal:  Infect Genet Evol       Date:  2018-02-17       Impact factor: 3.342

2.  Ectopic Expression of Plasmodium vivax vir Genes in P. falciparum Affects Cytoadhesion via Increased Expression of Specific var Genes.

Authors:  Torben Rehn; Pedro Lubiana; Thi Huyen Trang Nguyen; Eva Pansegrau; Marius Schmitt; Lisa Katharina Roth; Jana Brehmer; Thomas Roeder; Dániel Cadar; Nahla Galal Metwally; Iris Bruchhaus
Journal:  Microorganisms       Date:  2022-06-09

Review 3.  Developing Recombinant Antibodies by Phage Display Against Infectious Diseases and Toxins for Diagnostics and Therapy.

Authors:  Kristian Daniel Ralph Roth; Esther Veronika Wenzel; Maximilian Ruschig; Stephan Steinke; Nora Langreder; Philip Alexander Heine; Kai-Thomas Schneider; Rico Ballmann; Viola Fühner; Philipp Kuhn; Thomas Schirrmann; André Frenzel; Stefan Dübel; Maren Schubert; Gustavo Marçal Schmidt Garcia Moreira; Federico Bertoglio; Giulio Russo; Michael Hust
Journal:  Front Cell Infect Microbiol       Date:  2021-07-07       Impact factor: 5.293

4.  Genetic diversity of the Pvk12 gene in Plasmodium vivax from the China-Myanmar border area.

Authors:  Shuang Deng; Yonghua Ruan; Yao Bai; Yue Hu; Zeshuai Deng; Yongshu He; Rui Ruan; Yanrui Wu; Zhaoqing Yang; Liwang Cui
Journal:  Malar J       Date:  2016-11-04       Impact factor: 2.979

5.  Characterization of P. vivax blood stage transcriptomes from field isolates reveals similarities among infections and complex gene isoforms.

Authors:  Adam Kim; Jean Popovici; Amélie Vantaux; Reingsey Samreth; Sophalai Bin; Saorin Kim; Camille Roesch; Li Liang; Huw Davies; Philip Felgner; Sócrates Herrera; Myriam Arévalo-Herrera; Didier Ménard; David Serre
Journal:  Sci Rep       Date:  2017-08-10       Impact factor: 4.379

6.  Diversity of vir Genes in Plasmodium vivax from Endemic Regions in the Republic of Korea: an Initial Evaluation.

Authors:  Ui-Han Son; Sylvatrie-Danne Dinzouna-Boutamba; Sanghyun Lee; Hae Soo Yun; Jung-Yeon Kim; So-Young Joo; Sookwan Jeong; Man Hee Rhee; Yeonchul Hong; Dong-Il Chung; Dongmi Kwak; Youn-Kyoung Goo
Journal:  Korean J Parasitol       Date:  2017-04-30       Impact factor: 1.341

Review 7.  Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Authors:  Yehenew A Ebstie; Solomon M Abay; Wondmagegn T Tadesse; Dawit A Ejigu
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162

8.  Heterologous Expression of a Novel Drug Transporter from the Malaria Parasite Alters Resistance to Quinoline Antimalarials.

Authors:  Sarah M Tindall; Cindy Vallières; Dev H Lakhani; Farida Islahudin; Kang-Nee Ting; Simon V Avery
Journal:  Sci Rep       Date:  2018-02-06       Impact factor: 4.379

9.  Impact of the first-line treatment shift from dihydroartemisinin/piperaquine to artesunate/mefloquine on Plasmodium vivax drug susceptibility in Cambodia.

Authors:  Camille Roesch; Mélissa Mairet-Khedim; Saorin Kim; Dysoley Lek; Jean Popovici; Benoit Witkowski
Journal:  J Antimicrob Chemother       Date:  2020-07-01       Impact factor: 5.790

Review 10.  Recombinant antibodies for diagnostics and therapy against pathogens and toxins generated by phage display.

Authors:  Philipp Kuhn; Viola Fühner; Tobias Unkauf; Gustavo Marcal Schmidt Garcia Moreira; André Frenzel; Sebastian Miethe; Michael Hust
Journal:  Proteomics Clin Appl       Date:  2016-06-21       Impact factor: 3.494

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.